Posted by Michael Wonder on 25 Oct 2025
Agitated Solutions receives fast track designation for investigational drug ASI-02
23 October 2025 - ASI-02 is a novel contrast agent for cardiac bubble studies.
Agitated Solutions announced today that the US FDA has granted fast track designation for its inaugural product, ASI-02.
